JC18 Rec'd PCT/PTO 3 1 DEC 2001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of RHOLAM ET AL.

Examiner:

UNASSIGNED

Art Unit:

UNASSIGNED

Serial No.: 09/701,945

Filed:

DECEMBER 5, 2000

Title:

POLYPEPTIDES WHICH POSSESS

AN ACTIVITY OF THE β -

SECRETASE TYPE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents Washington, D.C. 20231

Sir:

 \boxtimes

In furtherance of requirements set forth in 37 C.F.R. 1,56, 1.97 AND 1.98 Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

(a) This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the

	Con	nmissioner	thorized to	charge any fees	under 3	.R. 1.17(p) or credit any
	over	payment to A	Account No. 1	18-1982.		
(b)	This	Information	Disclosure S	tatement is filed	after the per	iod set forth in 37 C.F.R.
	1.97	(b), but is be	lieved to be f	iled before the m	ailing date o	f a final action under §1.113 or
	a no	tice of allowa	ance under § 1	1.311, whichever	occurs first.	
	(1)	The undersi	gned attorne	y certifies that ea	ch item of ir	nformation contained in this
		Information	Disclosure S	Statement was cit	ed in a com	nunication from a foreign pater
		office in a c	ounterpart fo	reign application	not more th	an three months prior to the
		filing of thi	s statement;			
	(2)	The undersi	gned attorne	y certifies that no	item of info	ormation contained in this
		Information	Disclosure S	Statement was cit	ed in a com	nunication from a foreign pater
		office in a c	ounterpart fo	reign application	or, to the ki	nowledge of the undersigned
		attorney aft	er making rea	asonable inquiry,	was known	to any individual designated in
		§1.56(c) me	ore than three	months prior to	the filing of	this statement; or
	(3)	This Inform	ation Disclos	sure Statement is	accompanie	d by a transmittal letter in
		which payn	ent of the fee	e set forth in §1.1	7(p) and red	quired by 37 C.F.R. 1.97(c) is
		authorized.				
				Dogwootfully ou	hansitt od	
				Respectfully su		
				William C. Cop	pola, Reg. 1	No. 41,686

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-4854
Telefax (908) 231-2626

Attorney Docket No.: ST98014A

October 30, 2001

PTO/SB/08A (10-96)

•	ork Reduction Act of		o persons are required to res	App Patent and Tradem spond to collection of information			
	ite for form 1449A/PT		ATENT & THA	Or man factor if Managem			
				Application Number	9/701,945		
INF	ORMATION	1 DI	SCLOSURE	Filing Date	12-05-2000		
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	RHOLAM		
				Group Art Unit			
	(use as many she	eets as	s necessary)	Examiner Name			
Sheet	1	of	2	Attorney Docket Number	ST98014 A		

	U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	U.S. Paten Number	t Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
					 				
						-			
					<u> </u>				
									
ļ									
<u> </u>									
-									
			-++						
	-								

	FOREIGN PATENT DOCUMENTS										
Examiner	Cite	ļ ļ	oreign Patent Do	cument Kind Code ⁵	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant				
Initials*	No.1	Office ³	Number ⁴	(if known)	Applicant of Cited Document	MM-DD-YYYY	Figures Appear	T ⁶			
								+			
								+			
								+			
		 						+			
								\perp			

Examiner	Date	
Signature	Considered	
3		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this b	Please	type a	a plus	sian	(+)	inside	this	bo
---	--------	--------	--------	------	-----	--------	------	----



PTO/SB/08B (10-96)
se through 10/31/99. OMB 0651-0031
Patent and Trademark
U.S. DEPARTMENT OF COMMERCE
Illection of information united it contains a valid OMB control number

Substitut	e for form 1449B	PTO	WA TRAI	EMAN: Co	ompl te if Kn wn	
				Application Number	9/701,945	
INFO	PRMATIC	ON DI	SCLOSURE	Filing Date	12-05-2000	
STA	TEMEN ¹	r RY	APPLICANT	First Named Inventor	RHOLAM	
Oir				Group Art Unit		
	(use as mai	ny sheets i	as necessary)	Examiner Name		
Sheet	1	of	2	Attorney Docket Number	ST98014 /	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A\$	EVIN Genevieve et al., Alzheimer's Disease Amyloid Precursor Protein (ABPP): Proteolytic Processing, Secretases and BA4 Amyloid Production, Amyloid:Int. J Exp Clin. Invest I, 263-280 (1994)	
-			
_			
Examine		Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.